SOURCE: Sirona Biochem Corp.

Sirona Biochem Corp.

September 22, 2009 07:00 ET

Sirona Biochem to 'Accelerate' Drug Development After French Partner Opens State-of-the-Art Lab

VANCOUVER, BC--(Marketwire - September 22, 2009) - Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity, announced today that it is accelerating its drug development program following a visit to its French partner TFChem's new lab.

Mark Senner, President, who has just returned from TFChem's grand opening in Val de Reuil, stated, "It is outstanding that in the whole of France our partner TFChem was selected for unique government funding. It has resulted in what is now a truly world class state-of-the-art lab facility.

"Perhaps, more importantly for our shareholders, the additional researchers and equipment will allow us and our partner TFChem to make even greater strides, accelerating research into our unique family of molecules for obesity and diabetes drug development. Inevitably, we believe Sirona Biochem will benefit significantly."

Sirona Biochem owns the worldwide product rights to a library of sodium glucose transporter (SGLT) inhibitors to treat diabetes and obesity. SGLT Inhibitors block the reuptake of excess sugars from urine in the kidney, which can then reduce high blood sugar towards normal levels.

TFChem held a grand opening of its new 5,400 square foot lab that has been supported by French government funding in a PharmaParc close to all the major 'Big Pharma' companies in Val de Reuil, near Rouen, France.

TFChem's president, Dr.Géraldine Deliencourt-Godefroy, said, "This was the first funding operation of this type in France by the government and TFChem, with two other companies, uniquely, were the first selected. This is a major step for TFChem's development. All the team has now moved into the new laboratories."

"This event brought pharmaceutical companies and politicians to visit and learn more about TFChem's activities, and the partnership with Sirona on the development of new SGLT inhibitors. The first in vitro milestone we achieved in this program is also great news at this stage. It supports the efficacy of the GlycoMim® technology, and gives us confidence in our development plan," commented Dr. Deliencourt-Godefroy.

Sirona Biochem's website is at, where we feature the most recent information about the company and its activities. Alternatively, investors are able to e-mail all questions and correspondence to where they can also request to be added to the investor e-mail list to receive all future press releases and updates or call John Dougherty, Corporate Development at 604-641-4466.


TFChem, of Rouen, France, is a drug-discovery company which uses fluorine atom properties to develop new glycomimetic compounds: the GlycoMim® technology. TFChem is a leader in the area of fluorinated glycosides and their application as new, more potent and safer drugs. Through application of the patented core technology it is the intention to modify and discover new carbohydrate based drug compounds with increased therapeutic properties and clinical improvement potential.

Sirona Biochem

Sirona Biochem Corp. (TSX-V: SBM) is an emerging biotech company dedicated to the discovery and development of novel drug compounds. The current focus is on treatments for Type II Diabetes and Obesity. Sirona has entered into a license agreement with TFChem S.A.R.L., a Drug Discovery company based in Rouen, France. TFChem licenses its technology of fluorinated carbohydrate mimics: GlycoMim®, and products in development to biotech companies. The license agreement with TFChem provides for research and development of new compounds known as SGLT inhibitors. SGLT inhibitors are a new and exciting class of compounds that have great promise and potential to treat both diabetes and obesity.

   Mark Senner, President and Director

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Contact:
    John Dougherty
    Corporate Development